Edition:
United Kingdom

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

6.00USD
21 Sep 2018
Change (% chg)

$0.05 (+0.84%)
Prev Close
$5.95
Open
$6.00
Day's High
$6.05
Day's Low
$5.95
Volume
4,185
Avg. Vol
13,064
52-wk High
$13.30
52-wk Low
$4.80

Chart for

About

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $70.92
Shares Outstanding(Mil.): 10.79
Dividend: --
Yield (%): --

Financials

  TRIL.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -5.03 -- --
ROI: -52.37 1.78 14.61
ROE: -126.37 3.27 16.33

BRIEF-Trillium Therapeutics Provides Update On Its Clinical Programs

* TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CLINICAL PROGRAMS

10 Apr 2018

Earnings vs. Estimates